^
Association details:
| Biomarker: | CD20 expression |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) + Epkinly (epcoritamab-bysp) (CD20 inhibitor, CD3 agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1574 - Preclinical evaluation of epcoritamab combined with standard of care therapies for the treatment of B-cell lymphomas
Published date:
03/10/2021
Excerpt:
Here, we present in vitro studies conducted to evaluate whether epcoritamab can be used in combination with current SOC therapies for B-NHL….Lenalidomide enhanced T-cell activation induced by CD3 crosslinking with immobilized anti-CD3 or epcoritamab, resulting in higher potency of these T cells to exert epcoritamab-induced cytotoxicity of CD20-expressing tumor cells.
